Dupilumab-Induced Immune Drift Phenomena in Atopic Dermatitis: Novel Insights into Mechanisms and Therapeutic Strategies - PubMed
4 days ago
- #Dupilumab
- #Immune drift
- #Atopic dermatitis
- Dupilumab, targeting IL-4/IL-13, is a first-line biologic for moderate-to-severe atopic dermatitis (AD).
- Some AD patients develop psoriasiform eruptions post-treatment, while psoriasis patients may develop eczematous lesions, termed 'immune drift phenomenon.'
- The review covers immunological mechanisms, clinical and histopathological characteristics, temporal patterns, and therapeutic strategies for immune drift.
- Management approaches include topical therapies, systemic medication adjustments, biologic switching, and targeted small-molecule agents.
- Potential limitations of small-molecule inhibitors like JAK inhibitors or combination biologics are noted, including lack of long-term safety and efficacy data.
- Aims to provide evidence-based management recommendations and outline future research directions.